Cardiovascular Systems, Inc. Sustainability Profile
Cardiovascular Systems, Inc. (CSI) is a leading medical device company headquartered in the United States, specialising in innovative solutions for the treatment of cardiovascular disease. Founded in 1989, CSI has made significant strides in the industry, particularly with its advanced technologies designed to improve patient outcomes in peripheral and coronary artery disease. The company is renowned for its unique orbital atherectomy systems, which effectively remove plaque from arteries, enhancing blood flow and reducing the need for more invasive procedures. With a strong presence in major operational regions across North America and Europe, CSI has established itself as a key player in the cardiovascular sector. Notable achievements include numerous FDA approvals and a commitment to ongoing research and development, solidifying its market position as a trusted provider of cutting-edge cardiovascular solutions.
DitchCarbon Score
How does Cardiovascular Systems, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cardiovascular Systems, Inc.'s score of 54 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cardiovascular Systems, Inc., headquartered in the US, currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family that includes Abbott Laboratories, from which it inherits climate commitments and initiatives. Abbott Laboratories has established science-based targets for emissions reductions, which are cascaded down to Cardiovascular Systems, Inc. This includes commitments to reduce Scope 1 and Scope 2 emissions, as well as engaging in efforts to address Scope 3 emissions through supply chain management and product lifecycle assessments. While specific reduction targets for Cardiovascular Systems, Inc. are not detailed, the overarching goals set by Abbott Laboratories reflect a commitment to sustainability and climate action. As a current subsidiary of Abbott Laboratories, Cardiovascular Systems, Inc. aligns with industry standards and practices aimed at mitigating climate impact, although specific initiatives or targets for the subsidiary are not explicitly outlined. The company is expected to contribute to the broader climate goals set by its parent organisation, reinforcing its commitment to reducing carbon emissions and promoting environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 |
How Carbon Intensive is Cardiovascular Systems, Inc.'s Industry?
How Carbon Intensive is Cardiovascular Systems, Inc.'s Location?
Cardiovascular Systems, Inc.'s Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 71% of Scope 3 emissions.
Top Scope 3 Categories
Cardiovascular Systems, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cardiovascular Systems, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
